The Times Australia
Fisher and Paykel Appliances
The Times World News

.

GPs could improve access to ADHD treatment. But we still need specialists to diagnose and start medication

  • Written by Adam Guastella, Professor and Clinical Psychologist, Michael Crouch Chair in Child and Youth Mental Health, University of Sydney
GPs could improve access to ADHD treatment. But we still need specialists to diagnose and start medication

Attention deficit-hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects 2.5–5% of people[1]. Less than half[2] of people with ADHD have been diagnosed and treated – though more and more people are presenting[3] for help.

Like other neurodevelopmental conditions, there are long delays[4] to diagnosis. The current pathways to diagnosis and care can involve multiple assessments[5] from different professionals who are in short supply, making the process confusing, expensive and time-consuming.

Yet many Australians have a GP on local clinic they can access. That’s why some medical groups are advocating[6] for GPs to have a role in the diagnosis and management of ADHD.

But while GPs should have an expanded role in the ongoing management of ADHD, it’s important for specialists to diagnose and initiate treatment.

Read more: Myths and stigma about ADHD contribute to poorer mental health for those affected[7]

What is ADHD?

ADHD is associated with inattention, or difficulty holding and sustaining concentration over periods of time, particularly on tasks that are less interesting or require significant mental effort.

It is also often associated with hyperactivity and high levels of impulsivity and arousal, and difficulty planning, coordinating and remaining engaged in tasks.

In order to meet criteria for ADHD, these difficulties must be present over a long period and have a negative impact on a person’s day-to-day life. This is why an ADHD assessment requires a clinical interview from specialists, and should never be done by questionnaires alone.

ADHD assessments are performed by psychiatrists, paediatricians and clinical and neuropsychologists with specialist training.

Man helps young child with a puzzle
To meet the criteria, difficulties must impact on day to day life over a long period. Shutterstock[8]

An ADHD assessment must be comprehensive enough that if a diagnosis is made, it can be followed up with a management plan that:

  • addresses the person’s individual needs
  • is culturally appropriate for them and their circumstances
  • takes into consideration all of the issues identified.

When a diagnosis of ADHD is made, medication is often part of the management plan. Stimulant medications are usually the first-choice medication. Psychological therapies may also be recommended.

Treatment can ease some of the struggles

ADHD increases the risk for poor academic, occupational, social and mental health outcomes, and has even been associated with higher rates[9] of accidental injury and death.

However, these risks decrease when ADHD is effectively treated[10]. One front-line treatment, stimulants, have about a 70% efficacy rate[11] for managing symptoms. Research shows stimulants can effectively reduce[12] many of the adverse impacts of ADHD.

Stimulants have a good safety profile, with relatively few serious side effects[13] in most children and adults[14].

However, stimulants can be very hard to access. States and territories have different laws about stimulant prescribing[15], and your prescription from one state may not be honoured in another.

Why are medications difficult to access?

Stimulants are tightly regulated because they have been assessed as having the potential for abuse. Prescribing or supplying them requires prior authorisation by the state authorities and must be in accordance with criteria set out by each state.

While GPs and nurse practitioners can apply for authorisation in some situations in some states, the legislation generally identifies specialists (paediatricians and psychiatrists for children and adolescents, and psychiatrists for adults) as the main prescribers.

Currently, there are too few specialists, in both rural and urban areas of Australia, to ensure access to ADHD medication.

As our recognition of ADHD increases, especially in adults, alternative approaches are needed, since this skills shortage is unlikely to resolve soon.

Woman holds drink of water
Medication is often part of an ADHD management plan. Pexels/Lisa Fotois[16]

So what role should GPs have in managing ADHD?

We advocate for a “collaborative care” model, with GPs playing a greater role in managing patients’ ongoing ADHD care, including prescribing and monitoring medication.

However, it’s important for specialists to perform the initial diagnosis and identify the right treatment for the patient. Diagnosing ADHD can be complex – other psychiatric[17] and medical conditions may need to be ruled out. And it can be difficult[18] to match patients with an appropriate treatment.

GPs are specialists in chronic disease management and already provide ongoing care for many chronic physical and mental health conditions. GPs are generally easier and cheaper to access than other specialists, know their patients well and are embedded in their communities. Models of collaborative care for ADHD are already common[19] in many other countries including the United Kingdom and United States.

A collaborative care model would also allow specialists to spend more of their time on initial consults and the management of complex cases, rather than the ongoing management of less complex cases.

For collaborative care models to work, national programs will be required that can train and register GPs in ADHD management, to meet the needs of their patients with ADHD and, most importantly, improve patient outcomes.

Resources and support will be needed to ensure practitioners are supported[20] to deliver shared care for ADHD. If GPs don’t receive adequate support, fewer may be willing to provide this care.

Ultimately, the model could transform access to effective treatment for people with ADHD and their families.

Read more: You might have heard ADHD risks being over-diagnosed. Here's why that's not the case[21]

References

  1. ^ 2.5–5% of people (www.ncbi.nlm.nih.gov)
  2. ^ half (www.tandfonline.com)
  3. ^ presenting (www.abc.net.au)
  4. ^ long delays (bmjopen.bmj.com)
  5. ^ involve multiple assessments (theconversation.com)
  6. ^ advocating (www.racgp.org.au)
  7. ^ Myths and stigma about ADHD contribute to poorer mental health for those affected (theconversation.com)
  8. ^ Shutterstock (www.shutterstock.com)
  9. ^ higher rates (pubmed.ncbi.nlm.nih.gov)
  10. ^ effectively treated (pubmed.ncbi.nlm.nih.gov)
  11. ^ 70% efficacy rate (pubmed.ncbi.nlm.nih.gov)
  12. ^ reduce (pubmed.ncbi.nlm.nih.gov)
  13. ^ few serious side effects (pubmed.ncbi.nlm.nih.gov)
  14. ^ adults (pubmed.ncbi.nlm.nih.gov)
  15. ^ different laws about stimulant prescribing (aadpa.com.au)
  16. ^ Pexels/Lisa Fotois (www.pexels.com)
  17. ^ psychiatric (theconversation.com)
  18. ^ be difficult (pubmed.ncbi.nlm.nih.gov)
  19. ^ already common (bmcpsychiatry.biomedcentral.com)
  20. ^ supported (ncbi.nlm.nih.gov)
  21. ^ You might have heard ADHD risks being over-diagnosed. Here's why that's not the case (theconversation.com)

Read more https://theconversation.com/gps-could-improve-access-to-adhd-treatment-but-we-still-need-specialists-to-diagnose-and-start-medication-210803

Times Magazine

Can bigger-is-better ‘scaling laws’ keep AI improving forever? History says we can’t be too sure

OpenAI chief executive Sam Altman – perhaps the most prominent face of the artificial intellig...

A backlash against AI imagery in ads may have begun as brands promote ‘human-made’

In a wave of new ads, brands like Heineken, Polaroid and Cadbury have started hating on artifici...

Home batteries now four times the size as new installers enter the market

Australians are investing in larger home battery set ups than ever before with data showing the ...

Q&A with Freya Alexander – the young artist transforming co-working spaces into creative galleries

As the current Artist in Residence at Hub Australia, Freya Alexander is bringing colour and creativi...

This Christmas, Give the Navman Gift That Never Stops Giving – Safety

Protect your loved one’s drives with a Navman Dash Cam.  This Christmas don’t just give – prote...

Yoto now available in Kmart and The Memo, bringing screen-free storytelling to Australian families

Yoto, the kids’ audio platform inspiring creativity and imagination around the world, has launched i...

The Times Features

The rise of chatbot therapists: Why AI cannot replace human care

Some are dubbing AI as the fourth industrial revolution, with the sweeping changes it is propellin...

Australians Can Now Experience The World of Wicked Across Universal Studios Singapore and Resorts World Sentosa

This holiday season, Resorts World Sentosa (RWS), in partnership with Universal Pictures, Sentosa ...

Mineral vs chemical sunscreens? Science shows the difference is smaller than you think

“Mineral-only” sunscreens are making huge inroads[1] into the sunscreen market, driven by fears of “...

Here’s what new debt-to-income home loan caps mean for banks and borrowers

For the first time ever, the Australian banking regulator has announced it will impose new debt-...

Why the Mortgage Industry Needs More Women (And What We're Actually Doing About It)

I've been in fintech and the mortgage industry for about a year and a half now. My background is i...

Inflation jumps in October, adding to pressure on government to make budget savings

Annual inflation rose[1] to a 16-month high of 3.8% in October, adding to pressure on the govern...

Transforming Addiction Treatment Marketing Across Australasia & Southeast Asia

In a competitive and highly regulated space like addiction treatment, standing out online is no sm...

Aiper Scuba X1 Robotic Pool Cleaner Review: Powerful Cleaning, Smart Design

If you’re anything like me, the dream is a pool that always looks swimmable without you having to ha...

YepAI Emerges as AI Dark Horse, Launches V3 SuperAgent to Revolutionize E-commerce

November 24, 2025 – YepAI today announced the launch of its V3 SuperAgent, an enhanced AI platf...